List view / Grid view
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value…
15 August 2016 | By National Institute for Health and Care Excellence (NICE)
A higher dose of ticagrelor is already recommended for 12 months after a heart attack. Now new draft guidance is recommending it is continued in these people at a lower dose for a further three years to reduce their risk of a further heart attack or stroke...
8 August 2016 | By Bristol-Myers Squibb
The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access…
4 August 2016 | By National Institute for Health and Care Excellence (NICE)
The National Institute for Health and Care Excellence (NICE) has recommended innovative new drug secukinumab for treating ankylosing spondylitis, a type of arthritis that mainly affects the back....
15 July 2016 | By National Institute for Health and Care Excellent (NICE)
NICE is advertising for five Non-Executive Directors to help NICE improve outcomes for people using the NHS, public health and social care services...
12 July 2016 | By Victoria White, Digital Content Producer
Certolizumab pegol is recommended as an option for people with severe rheumatoid arthritis when other drugs haven’t worked or aren’t suitable...
8 July 2016 | By Victoria White, Digital Content Producer
Eisai has expressed concern that patients in England and Wales will have to wait three years to access Lenvatinib due to a ‘black hole’ in the CDF process...
7 July 2016 | By Victoria White, Digital Content Producer
Bosutinib is the first drug to go through the reappraisal process, where NICE assesses the cost and clinical effectiveness of drugs currently in the old CDF...
1 July 2016 | By Victoria White, Digital Content Producer
NICE has recommended Ferring’s Firmagon (degarelix) for men with advanced-hormone dependent prostate cancer and spinal metastases...
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
17 June 2016 | By Victoria White, Digital Content Producer
The NHS will receive a discount on the combination treatment agreed between Bristol-Myers Squibb and the Department of Health...
17 June 2016 | By Victoria White, Digital Content Producer
NICE has said it will not be able to recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis...
1 June 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has asked Janssen to set out a case for including its chronic lymphocytic leukaemia (CLL) drug ibrutinib (Imbruvica) in the Cancer Drugs Fund (CDF).
25 May 2016 | By Victoria White, Digital Content Producer
Jevtana has been recommended in combination with other drugs as a treatment option for metastatic hormone-relapsed prostate cancer in England...
25 May 2016 | By Victoria White, Digital Content Producer
NICE has published final guidance recommending three drugs for treating type 2 diabetes: canagliflozin, dapagliflozin and empagliflozin...
